
11 Jan 2019 Research
Myelofibrosis: Finding new ways to treat patients
Myelofibrosis is a fatal bone marrow cancer. The disease is caused by excessive secretion of factors by cancerous platelet-producing cells called megakaryocytes. These secretions cause the replacement of normal bone marrow tissue with fibrous scar tissue.
Dr Chen’s team can successfully recreate this pathological bone marrow environment in the laboratory, and their preliminary research data shows that reduced levels of a protein complex called FANCcore leads to more myelofibrosis.
Dr Chen’s team hypothesise that loss of the protein complex FANCcore increases the growth of myelfibrosis by altering megakaryocytes. Dr Chen uses both human tissue cultures and mouse models to examine the cellular and molecular changes to megakaryocytes following the absence of the FANCcore complex and to understand how these changes cause myelofibrosis.
The team hopes that by focusing on the role of FANCcore in megakaryocyte biology, they can reveal new ways to treat myelofibrosis.
Related posts
23 September 2022
Spectacular sailing challenge in memory of Pat Buckley
Royal Corinthian Yacht Club’s 61st Endeavour Trophy fundraiser for Leukaemia UK A fleet of thirty boats displaying the Leukaemia UK logo on their sails will put on a spectacular racing…
16 November 2022
Cost of Living with Leukaemia Fund launches
Leukaemia Care and Leukaemia UK have launched a new financial support service, the Cost of Living with Leukaemia Fund, in response to the cost of living crisis in the UK….
9 January 2018
Blood cancer and your emotions – an expert’s insight
Specialist blood cancer counsellor Philip Alexander explains why talking therapies can form a crucial part of treatment
5 December 2022
John Goldman Fellowships for 2023 now open
Leukaemia UK is delighted to announce that we are funding more ground-breaking research in 2023, by continuing our investment in early career scientists and clinicians for our prestigious John Goldman…